ORACLE INDUSTRY CONNECT, WASHINGTON DC-March 26, 2015-Contract research organizations (CROs) are constantly looking for ways to improve project oversight and reduce costs while adding value and simplifying data exchange-especially in complex clinical trials involving multiple CRO partners. Pharmaceutical Product Development, LLC (PPD), a leading global CRO, looked to Oracle Health Sciences Cloud for a solution. PPD is the first CRO to migrate trials from an onsite installation of Oracle’s Siebel Clinical Trial Management System to Siebel Clinical Trial Management System Cloud Service-creating a highly available, centralized-trial database that lowers costs, simplifies the management and improves the accuracy of multi-CRO clinical trial data, and accelerates studies. Ovum recognized Siebel Clinical Trial Management System as a market leader in its “Ovum Decision Matrix: Selecting a CTMS Solution, 2013–14” report.
“Oracle Siebel Clinical Trial Management System Cloud Service dramatically simplifies how we manage study data and communicate with clients, especially in studies involving multiple CROs,” said Andrew Masters, vice president of enterprise information management, PPD. “Clients can now access study data through Oracle’s Siebel cloud Service, so we no longer need to send data back and forth to them, saving us time, reducing the cost of studies and creating better results for our clients.”
Using Siebel Clinical Trial Management System Cloud Service with a standardized clinical trial management system (CTMS) configuration, PPD migrated data from 124 studies to the Oracle Health Sciences Cloud in just six weeks, achieving rapid time to value. In addition, the organization is reducing the in-house resources needed to support these trials by using the cloud to simplify the exchange of data for multi-CRO studies. With the highly available and secure monitoring cloud, PPD and trial sponsors gain actionable insight into studies to accelerate clinical development while reducing trial costs and risk.
“Oracle’s Siebel Clinical Trial Management System Cloud Service delivers comprehensive clinical trial management with all the performance, scalability, and cost benefits of Oracle Health Sciences Cloud,” said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. “The success of PPD, one of the world’s largest CROs, in rapidly migrating data from an on-premises environment to Siebel Clinical Trial Management System Cloud Service demonstrates the flexibility of the solution and its ability to simplify data exchange, ultimately leading to more-efficient clinical trial management.”
Siebel Clinical Trial Management System combines standardized, comprehensive clinical trial capabilities, integrated analytics tools, and unsurpassed data security with a cloud service that lets organizations effectively and economically manage clinical trial activities and improve CRO and sponsor relationships from early to late-stage clinical trials.
Validating Oracle’s industry leadership, Ovum, a leading IT research and analyst group, has positioned Siebel Clinical Trial Management System as a market leader in its “Ovum Decision Matrix: Selecting a CTMS Solution, 2013–14” report based on “its market share, breadth of offering, and long-term vision.” This report compares products of the top five CTMS vendors to help life sciences organizations better understand the CTMS vendor landscape. Siebel Clinical Trial Management System led the technology assessment category, scoring highest in breadth of offering, usability, development, and reporting.
“Ovum designates a market leader as having established a commanding market position with a product that is widely accepted as best of breed and worthy of a place on most technology selection shortlists,” said Andrew Brosnan, senior analyst, Ovum Health Sciences team. “Oracle’s support for mobile CRAs, risk-based monitoring platform, and integration with its Oracle Health Sciences Clinical Development Analytics product differentiates its offering from the rest of the market.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.